8-K: Dare Bioscience Announces Phase 3 Clinical Trial Plans for Sildenafil Cream for Female Sexual Arousal Disorder

Dare Bioscience has announced plans for a Phase 3 clinical trial of Sildenafil Cream for the treatment of female sexual arousal disorder (FSAD), following discussions with the FDA.

Summary

• Dare Bioscience is moving forward with Phase 3 clinical trials for Sildenafil Cream, a topical treatment for female sexual arousal disorder (FSAD).
• The company plans to submit the trial protocol and statistical analysis plan to the FDA in the first quarter of 2025, with the study expected to begin in mid-2025.
• The Phase 3 study will be a 12-week double-blind trial comparing Sildenafil Cream to a placebo cream.
• The study will use the same co-primary endpoints as the Phase 2b RESPOND study, assessing arousal sensations and associated distress.
• Secondary endpoints will include improvements in orgasm, desire, distress, and interpersonal difficulties.
• A second confirmatory Phase 3 study will be required for FDA approval.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the potential of Sildenafil Cream and the progress towards Phase 3 trials. However, it also acknowledges the risks and uncertainties associated with drug development, which tempers the overall sentiment.

Positives

• Sildenafil Cream has the potential to be the first FDA-approved treatment for FSAD.
• The Phase 3 trial design reflects FDA feedback, increasing the likelihood of a successful study.
• The company is targeting a mid-2025 start for the Phase 3 study, indicating a clear timeline.
• The market for FSAD treatments is estimated to be significant, with approximately 10 million women in the U.S. seeking solutions.
• The Phase 3 study will use the same endpoints as the Phase 2b study, which should provide consistency and comparability.

Negatives

• A second confirmatory Phase 3 study will be required, which will add time and cost to the approval process.
• The company acknowledges the inherent uncertainty of clinical trial outcomes, particularly for FSAD.
• There is a risk that the Phase 3 study may not demonstrate statistically significant differences between Sildenafil Cream and placebo.
• The company's ability to advance the development of Sildenafil Cream is dependent on securing sufficient capital resources.

Risks

• There is a risk of insufficient capital to advance the development of Sildenafil Cream.
• The company faces potential delays in starting, conducting, and completing clinical trials.
• The outcomes of clinical trials are inherently uncertain, especially for complex conditions like FSAD.
• The FDA may not agree with the company's interpretation of clinical data.
• The company depends on third parties for clinical trials and manufacturing.
• There is a risk of competition from other companies developing treatments for FSAD.
• The company may face difficulties in obtaining market acceptance or adequate reimbursement for Sildenafil Cream.
• The company's intellectual property rights may not be adequately protected or enforced.

Future Outlook

Dare Bioscience plans to submit the Phase 3 protocol to the FDA in the first quarter of 2025 and aims to commence the Phase 3 study in mid-2025, with the goal of obtaining FDA approval for Sildenafil Cream as a treatment for FSAD.

Management Comments

• Sabrina Martucci Johnson, President and CEO of Dare Bioscience, stated that they have appreciated the FDA's collaboration on the Phase 3 design.
• She also expressed excitement about the potential for Sildenafil Cream to address the unmet need in women's sexual health.

Industry Context

This announcement is significant as there are currently no FDA-approved pharmacological treatments for FSAD, making Sildenafil Cream a potential first-in-category treatment. The development of a topical treatment addresses the need for a more targeted approach with fewer systemic side effects compared to oral medications.

Comparison to Industry Standards

• The development of Sildenafil Cream for FSAD is analogous to the development of sildenafil (Viagra) for erectile dysfunction (ED) in men, which is a well-established market.
• The Phase 3 trial design, including the use of co-primary endpoints, is consistent with the approach used for approved ED treatments.
• The company is using the same endpoints as their Phase 2b study, which is a common practice to ensure consistency and comparability of results.
• The market size for FSAD is estimated to be significant, with approximately 10 million women in the U.S. seeking solutions, which is comparable to the market size for ED treatments.

Stakeholder Impact

• Shareholders may see this as a positive step towards commercializing Sildenafil Cream.
• Employees may be impacted by the progress of the clinical trials and the company's financial stability.
• Customers (women with FSAD) may benefit from a new treatment option.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Dare Bioscience will submit the Phase 3 protocol and statistical analysis plan to the FDA in the first quarter of 2025.
• The company is targeting mid-2025 for the commencement of the Phase 3 study.
• A second confirmatory Phase 3 study will be required to support the NDA submission.

Key Dates

Keywords

Sildenafil Cream, Female Sexual Arousal Disorder, FSAD, Phase 3 Clinical Trial, FDA Approval, Women's Health, Topical Treatment, Sexual Dysfunction, Clinical Study, Drug Development